RedHill's RHB-204 Matches RHB-104 in MAP-Killing Lab Studies
Image
RALEIGH – November 02, 2026 -- RedHill Biopharma (NASDAQ: RDHL) said two independent in vitro studies confirmed that its Crohn's disease candidate RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) at a level comparable to RHB-104, which posted a 64% efficacy gain in a Phase 3 trial.
Two microbiology centers confirm MAP-killing in culture and phage assays
The studies used long-term intracellular culture and spot and phage assays. One was led by Professor Tim Bull of City St George's University of London. The other was led by Professor Irene Grant of Queen's University Belfast and Dr Hannah Dane, working with Rapid-myco Technologies.